Disclosed are ophthalmic compositions, methods for using the compositions and kits comprising the compositions for treating dry eye in a subject in need thereof. The composition comprises at least one peptide that is an inhibitor of trans-endothelial migration, an analogue, variant, derivative, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient for treating dry eye and ocular diseases of inflammation.

Disclosed are ophthalmic compositions, methods for using the compositions and kits comprising the compositions for treating dry eye in a subject in need thereof. The composition comprises at least one peptide that is an inhibitor of trans-endothelial migration, an analogue, variant, derivative, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient for treating dry eye and ocular diseases of inflammation.

The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.

The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.

The present invention is directed to compounds according to Formula (I) and the pharmaceutically acceptable salts thereof. The compounds can be used as modulators of Estrogen-related Receptor alpha (ERRα) and have utility in the treatment of ERRα-mediated diseases or conditions.

##STR00001##

The present invention is directed to compounds according to Formula (I) and the pharmaceutically acceptable salts thereof. The compounds can be used as modulators of Estrogen-related Receptor alpha (ERRα) and have utility in the treatment of ERRα-mediated diseases or conditions.

##STR00001##

HIV pre-exposure prophylaxis (PrEP) has been available for nearly a decade. Patients can take a pill comprising of multiple antiviral agents that, if exposed to HIV, will prevent a permanent viral infection with an extremely high success rate. However, the use of PrEP antivirals has been linked to higher rates of STIs including HSV-1, HSV-2, Infectious Mononucleosis, chlamydia, gonorrhea, trichomanias, and syphilis. In particular, Herpes Simplex Viruses 1 and 2 can cause symptoms including oral or genital sores, while mono, caused by the Epstein-Barr Virus, can cause prolonged sickness. This disclosure utilizes two or more antiviral agents as a multi-use therapy for both suppressing a chronic herpesvirus infection while preventing an HIV infection. With this therapy, the odds of both acquiring HIV or spreading a herpesvirus are greatly reduced during human contact.

HIV pre-exposure prophylaxis (PrEP) has been available for nearly a decade. Patients can take a pill comprising of multiple antiviral agents that, if exposed to HIV, will prevent a permanent viral infection with an extremely high success rate. However, the use of PrEP antivirals has been linked to higher rates of STIs including HSV-1, HSV-2, Infectious Mononucleosis, chlamydia, gonorrhea, trichomanias, and syphilis. In particular, Herpes Simplex Viruses 1 and 2 can cause symptoms including oral or genital sores, while mono, caused by the Epstein-Barr Virus, can cause prolonged sickness. This disclosure utilizes two or more antiviral agents as a multi-use therapy for both suppressing a chronic herpesvirus infection while preventing an HIV infection. With this therapy, the odds of both acquiring HIV or spreading a herpesvirus are greatly reduced during human contact.

The present invention is related to the discovery of new oral dosage formulations and combination therapies for 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof, for treating conditions ameliorated by inhibition of IRAK4.

The present invention is related to the discovery of new oral dosage formulations and combination therapies for 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof, for treating conditions ameliorated by inhibition of IRAK4.